StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

BioNexus Gene Lab's operating cash flow for the twelve months ending Jun 30, 2026 was -$846.57K. For fiscal 2025 it was -$1.84M. The highest annual figure on record is $552.68K in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.84M–
FY2024Dec 31, 2024-$2.09M–
FY2023Dec 31, 2023-$1.82M-430.2%
FY2022Dec 31, 2022$551.82K+5923.6%
FY2021Dec 31, 2021$9.16K-98.3%
FY2020Dec 31, 2020$552.68K–
FY2019Dec 31, 2019-$217.27K–
FY2018Dec 31, 2018-$274.08K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$422.49K–
Q1 FY2026Mar 31, 2026-$147.67K–
Q4 FY2025Dec 31, 2025$961.06K+338.4%
Q3 FY2025Sep 30, 2025-$1.24M–
Q2 FY2025Jun 30, 2025-$737.91K–
Q1 FY2025Mar 31, 2025-$824.07K–
Q4 FY2024Dec 31, 2024$219.20K–
Q3 FY2024Sep 30, 2024-$1.60M–
Q2 FY2024Jun 30, 2024-$672.28K–
Q1 FY2024Mar 31, 2024-$37.15K–
Q4 FY2023Dec 31, 2023-$782.53K-264.1%
Q3 FY2023Sep 30, 2023-$899.35K-391.2%
Q2 FY2023Jun 30, 2023-$23.82K–
Q1 FY2023Mar 31, 2023-$116.52K–
Q4 FY2022Dec 31, 2022$476.74K-1.3%
Q3 FY2022Sep 30, 2022$308.89K-2.2%
Q2 FY2022Jun 30, 2022-$195.97K–
Q1 FY2022Mar 31, 2022-$37.84K-132.8%
Q4 FY2021Dec 31, 2021$483.01K-48.2%
Q3 FY2021Sep 30, 2021$315.87K-58.1%
Q2 FY2021Jun 30, 2021-$905.14K–
Q1 FY2021Mar 31, 2021$115.43K–
Q4 FY2020Dec 31, 2020$932.48K–
Q3 FY2020Sep 30, 2020$754.74K–
Q2 FY2020Jun 30, 2020-$157.20K–
Q1 FY2020Mar 31, 2020-$977.35K–
Q4 FY2019Dec 31, 2019-$58.36K-123.9%
Q3 FY2019Sep 30, 2019-$57.42K-132.5%
Q2 FY2019Jun 30, 2019-$52.94K–
Q1 FY2019Mar 31, 2019-$48.56K–
Q4 FY2018Dec 31, 2018$243.79K–
Q3 FY2018Sep 30, 2018$176.53K–
Q2 FY2018Jun 30, 2018-$20.83K–
Q1 FY2018Mar 31, 2018-$673.56K–

More BioNexus Gene Lab figures

See a number that looks wrong?